Related Experiment Videos
Treatment of growth hormone deficiency
Insights
Early diagnosis and tailored growth hormone (GH) therapy, including dose adjustments during puberty, are crucial for treating children with GH deficiency (GHD). Optimal treatment prevents short stature in GHD patients.
Area of Science:
- Pediatric Endocrinology
- Growth Hormone Therapy
- Hormone Replacement
Background:
- Growth Hormone Deficiency (GHD) in children can lead to significant short stature.
- Early diagnosis and appropriate management are essential for optimal growth outcomes.
- Advances in diagnostics and treatment have improved the prognosis for GHD patients.
Purpose of the Study:
- To provide evidence-based recommendations for the treatment of GHD in children.
- To outline optimal dosing and administration strategies for growth hormone therapy.
- To discuss adjunctive hormone replacement therapies for associated endocrine deficiencies.
Main Methods:
- Review of existing literature and clinical experience.
- Analysis of growth hormone dosing strategies for prepubertal and pubertal children.
- Evaluation of hormone replacement protocols for hypothyroidism, hypocortisolism, and hypogonadism.
Main Results:
- Recommended growth hormone (GH) dose of at least 12 IU/m2 per week for prepubertal children, with dose increases during puberty.
- Daily subcutaneous injections are the preferred method of GH administration.
- Guidelines for thyroxine, glucocorticoid, and sex steroid replacement in GHD patients with multiple pituitary hormone deficiencies.
Conclusions:
- Timely diagnosis and GH replacement therapy can prevent dwarfism in children with GHD.
- Individualized treatment plans, including appropriate hormone replacement, are key to achieving optimal growth.
- Growth hormone releasing factors remain experimental for GHD treatment.
Abstract:
According to the results reported in the literature and from our own experience, the following recommendations for the treatment of children with GHD can be given: In order to start GH replacement therapy in early childhood the diagnosis of GHD should be made as early as possible. The growth hormone dose during prepubertal age should not fall short of 12 IU/m2 per week. During spontaneous or induced puberty, the dose needs to be increased, possibly by a factor of two. Daily subcutaneous injections appear most suitable. Treatment with growth hormone releasing factors in cases with hypothalamic GHD, although a promising alternative to the treatment with hGH (Thorner et al, 1985), must be considered experimental at this point. Thyroxine replacement at a daily dose of 75-100 micrograms/m2 should be given in cases of secondary hypothyroidism. Glucocorticoid replacement, if required, should be given at low doses (e.g. hydrocortisone 10 (to 15) mg/m2 per day in divided doses). In cases with additional gonadotropin deficiency, sex steroids (or anabolic steroids) should be given with frequent monitoring of bone maturity not before the age of 13 in girls or 15 years in boys. In boys depot testosterone starting at low doses (e.g. 50-100 mg/month i.m.) will induce a puberty-like increment in height velocity. Since the effect of oestrogens--even in low doses--on growth is uncertain, their administration before achievement of near-normal adult height should be avoided. With the advancement of diagnostic techniques and with the experience in treatment accumulated over the past 25 years, patients with GHD need no longer become dwarfs.